ERBB2 and neoplasm: Additionally, the mapping of all mutations in 31 tumor types to variant interpretations merged from three genetic knowledge bases showed BC to have the greatest fraction of patients who might benefit from existing investigational targeted therapies, due to frequent mutations of AKT1, ERBB2, and PIK3CA [58].